Výsledky vyhledávání - "Ferran J Garcia Fructuoso"

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study

Autor: Stephen J. Rozzo, Alan M. Mendelsohn, Alice B. Gottlieb, Siba P. Raychaudhuri, Proton Rahman, Saima Chohan, Philip J. Mease, Richard C Chou, Michael E. Luggen, Ferran J Garcia Fructuoso

Publikováno v: Annals of the Rheumatic Diseases

ObjectivesTo evaluate efficacy and safety of the anti-interleukin-23p19 monoclonal antibody tildrakizumab in patients with psoriatic arthritis (PsA).MethodsIn this randomised, double-blind, placebo-controlled, phase IIb study, patients with active Ps

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45699aa413018d161e9029b076da7135
https://doi.org/10.1136/annrheumdis-2020-219014

Zobrazit plný text záznamu

LB0002 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 2B STUDY TO DEMONSTRATE THE SAFETY AND EFFICACY OF TILDRAKIZUMAB, A HIGH-AFFINITY ANTI-INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Autor: Ferran J Garcia Fructuoso, Kristine E Nograles, Philip J. Mease, Saima Chohan, Richard C Chou, Michael E. Luggen, Alan M. Mendelsohn

Publikováno v: Oral Presentations.

Background Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for psoriatic arthritis (PsA). Objectives To evaluate the 24-week e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::737e7ee25e5e432baf497dc8bb5b5ead
https://doi.org/10.1136/annrheumdis-2019-eular.8669

Zobrazit plný text záznamu